Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business
Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01)
New data demonstrate protective effects in viral infections beyond